These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 39289058)

  • 1. Clinical Update on an Anti-Alzheimer Drug Candidate CT1812: A Sigma-2 Receptor Antagonist.
    Kaur G; Dar ZA; Bajpai A; Singh R; Bansal R
    Clin Ther; 2024 Sep; ():. PubMed ID: 39289058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CT1812, a Small Molecule Sigma-2 Receptor Antagonist for Alzheimer's Disease Treatment: A Systematic Review of Available Clinical Data.
    Thitilertdecha P; Brimson JM
    J Alzheimers Dis; 2024; 101(s1):S115-S128. PubMed ID: 39422939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.
    Izzo NJ; Yuede CM; LaBarbera KM; Limegrover CS; Rehak C; Yurko R; Waybright L; Look G; Rishton G; Safferstein H; Hamby ME; Williams C; Sadlek K; Edwards HM; Davis CS; Grundman M; Schneider LS; DeKosky ST; Chelsky D; Pike I; Henstridge C; Blennow K; Zetterberg H; LeVine H; Spires-Jones TL; Cirrito JR; Catalano SM
    Alzheimers Dement; 2021 Aug; 17(8):1365-1382. PubMed ID: 33559354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer's disease.
    van Dyck CH; Mecca AP; O'Dell RS; Bartlett HH; Diepenbrock NG; Huang Y; Hamby ME; Grundman M; Catalano SM; Caggiano AO; Carson RE
    Alzheimers Res Ther; 2024 Jan; 16(1):20. PubMed ID: 38273408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's disease.
    Lizama BN; North HA; Pandey K; Williams C; Duong D; Cho E; Di Caro V; Ping L; Blennow K; Zetterberg H; Lah J; Levey AI; Grundman M; Caggiano AO; Seyfried NT; Hamby ME
    Neurobiol Dis; 2024 Sep; 199():106575. PubMed ID: 38914170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CT1812 biomarker signature from a meta-analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease.
    Lizama BN; Williams C; North HA; Pandey K; Duong D; Di Caro V; Mecca AP; Blennow K; Zetterberg H; Levey AI; Grundman M; van Dyck CH; Caggiano AO; Seyfried NT; Hamby ME
    Alzheimers Dement; 2024 Oct; 20(10):6860-6880. PubMed ID: 39166791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease.
    Grundman M; Morgan R; Lickliter JD; Schneider LS; DeKosky S; Izzo NJ; Guttendorf R; Higgin M; Pribyl J; Mozzoni K; Safferstein H; Catalano SM
    Alzheimers Dement (N Y); 2019; 5():20-26. PubMed ID: 30723776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Allosteric Antagonist of the Sigma-2 Receptors-Elayta (CT1812) as a Therapeutic Candidate for Mild to Moderate Alzheimer's Disease: A Scoping Systematic Review.
    Rasheed A; Zaheer AB; Munawwar A; Sarfraz Z; Sarfraz A; Robles-Velasco K; Cherrez-Ojeda I
    Life (Basel); 2022 Dec; 13(1):. PubMed ID: 36675950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer's Disease.
    Rishton GM; Look GC; Ni ZJ; Zhang J; Wang Y; Huang Y; Wu X; Izzo NJ; LaBarbera KM; Limegrover CS; Rehak C; Yurko R; Catalano SM
    ACS Med Chem Lett; 2021 Sep; 12(9):1389-1395. PubMed ID: 34531947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity.
    Izzo NJ; Xu J; Zeng C; Kirk MJ; Mozzoni K; Silky C; Rehak C; Yurko R; Look G; Rishton G; Safferstein H; Cruchaga C; Goate A; Cahill MA; Arancio O; Mach RH; Craven R; Head E; LeVine H; Spires-Jones TL; Catalano SM
    PLoS One; 2014; 9(11):e111899. PubMed ID: 25390692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer's disease.
    Colom-Cadena M; Toombs J; Simzer E; Holt K; McGeachan R; Tulloch J; Jackson RJ; Catterson JH; Spires-Jones MP; Rose J; Waybright L; Caggiano AO; King D; Gobbo F; Davies C; Hooley M; Dunnett S; Tempelaar R; Meftah S; Tzioras M; Hamby ME; Izzo NJ; Catalano SM; Durrant CS; Smith C; Dando O; Spires-Jones TL
    Acta Neuropathol; 2024 Feb; 147(1):32. PubMed ID: 38319380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
    Tolar M; Abushakra S; Hey JA; Porsteinsson A; Sabbagh M
    Alzheimers Res Ther; 2020 Aug; 12(1):95. PubMed ID: 32787971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.
    Izzo NJ; Staniszewski A; To L; Fa M; Teich AF; Saeed F; Wostein H; Walko T; Vaswani A; Wardius M; Syed Z; Ravenscroft J; Mozzoni K; Silky C; Rehak C; Yurko R; Finn P; Look G; Rishton G; Safferstein H; Miller M; Johanson C; Stopa E; Windisch M; Hutter-Paier B; Shamloo M; Arancio O; LeVine H; Catalano SM
    PLoS One; 2014; 9(11):e111898. PubMed ID: 25390368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's disease and clinical trials.
    Paul D; Agrawal R; Singh S
    J Basic Clin Physiol Pharmacol; 2024 Jan; 35(1-2):31-44. PubMed ID: 38491747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's protection effect of A673T mutation may be driven by lower Aβ oligomer binding affinity.
    Limegrover CS; LeVine H; Izzo NJ; Yurko R; Mozzoni K; Rehak C; Sadlek K; Safferstein H; Catalano SM
    J Neurochem; 2021 May; 157(4):1316-1330. PubMed ID: 33025581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer's Disease.
    Krafft GA; Jerecic J; Siemers E; Cline EN
    Front Neurosci; 2022; 16():848215. PubMed ID: 35557606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression.
    Tolar M; Hey J; Power A; Abushakra S
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34198582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer's Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data.
    Kocis P; Tolar M; Yu J; Sinko W; Ray S; Blennow K; Fillit H; Hey JA
    CNS Drugs; 2017 Jun; 31(6):495-509. PubMed ID: 28435985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sigma ligands as potent inhibitors of Aβ and AβOs in neurons and promising therapeutic agents of Alzheimer's disease.
    Ma WH; Chen AF; Xie XY; Huang YS
    Neuropharmacology; 2021 Jun; 190():108342. PubMed ID: 33045243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer's Disease.
    Uddin MS; Kabir MT; Rahman MS; Behl T; Jeandet P; Ashraf GM; Najda A; Bin-Jumah MN; El-Seedi HR; Abdel-Daim MM
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.